ST. JOSEPH, Mich., Oct. 30 GeneGo, Inc., the leadingsystems biology tools company, announced today that Elan Pharmaceuticals, Inc.licensed its flagship data analysis suite MetaCore(TM). The platform will beavailable to all scientists in research. MetaCore is designed for functionalanalysis of biological and chemistry data. Elan will use MetaCore in theirneurology and autoimmune programs.
"We are very pleased that Elan chose GeneGo and we have had goodinteractions so far," said Julie Bryant, GeneGo's VP of Business development."MetaCore has substantial knowledge content coverage in the areas of CNS andautoimmune diseases, which the Elan scientists can leverage in theirinnovative research."
GeneGo develops systems biology technology for life science research. Theoriginal computational MetaDiscovery(TM) platform allows an integration andexpert analysis of different kinds of experimental data (mRNA expression,proteomics, metabolomics, microRNA assays and other phenotypic data) andrelevant bioactive chemistry (metabolites, drugs, other xenobiotics) withinthe framework of curated biological pathways and networks. GeneGo's flagshipproduct, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas oftarget selection and validation, identification of biomarkers for diseasestates and toxicology. The second product, MetaDrug 4.5(TM) is designed forprediction of human metabolism, toxicity and biological effects for novelsmall molecules compounds. MetaBase(TM) represents the knowledge base forMetaCore. For more information, please visit the company's web site athttp://www.genego.com.
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM),MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo,Inc.
SOURCE GeneGo, Inc.